Misty Good, MD, MS, Associate Professor of Pediatrics, Division Chief of Neonatal-Perinatal Medicine and Co-Director of Carolina Child Health Scholars Program, was recently elected to membership of the American Society for Clinical Investigation.
Founded in 1908, the American Society for Clinical Investigation is one of the oldest and most esteemed nonprofit honor societies of physician-scientists. Membership is by election only, and only researchers who are 50 years of age or younger are eligible for nomination to the Society. Therefore, membership in the ASCI is a recognition of a researcher’s significant contributions, at a relatively young age, to the understanding of human disease. The Society counts among its ranks more than 3,000 members, many of whom are leaders in academic medicine and industry. Many members have been recognized with election to the U.S. National Academy of Sciences and the National Academy of Medicine. The ASCI is also proud to have among its membership winners of the Nobel Prize and the Lasker Award. The ASCI convenes an annual meeting with the Association of American Physicians and American Physician Scientists Association, and the Society self-publishes the prestigious Journal of Clinical Investigation (founded 1924) and JCI Insight (founded 2016).
Dr. Good’s Laboratory is focused on the cellular and molecular mechanisms involved in the pathogenesis of a devastating intestinal disease primarily affecting premature infants called necrotizing enterocolitis (NEC). The long-term goal of the Good Lab is to understand the signaling pathways regulating the uncontrolled immune response in NEC and how these responses can be prevented through dietary modifications or targeted intestinal epithelial therapies. Her basic and translational research utilizes a bench-to-bedside approach with multiple cutting-edge techniques. In her pre-clinical studies, their team utilizes a humanized neonatal mouse model of NEC to understand the signaling pathways and immune cell responses involved in NEC development. Specifically, the laboratory interrogates ways to modulate the immune response, epithelial cell and stem cell regeneration as well as early microbial colonization during NEC. In the clinical component of her research program, Dr. Good leads a large multi-center NEC biorepository for the dedicated pursuit of molecular indicators of disease and to gain greater pathophysiologic insights during NEC in humans. Dr. Good also developed a premature infant intestine-on-a-chip model to study NEC and provide a personalized medicine approach to test new therapeutics. Her laboratory is currently funded with multiple NIH R01 grants and has previously received K08 and R03 funding as well as awards from the March of Dimes, the Gerber Foundation and the NEC Society.
Congratulations, Dr. Good!